Molecular Partners $64 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Ayala Pharmaceuticals $20 million at-the-market offering
We advised the sales agent on the stock offering
UiPath $1.54 billion IPO
The shares are listed on the New York Stock Exchange
Akoya Biosciences $151.3 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Beam Therapeutics $300 million at-the-market offering
We advised the sales agent in connection with the equity offering
LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock
loanDepot $600 million senior notes offering
We advised the initial purchasers on the high-yield debt offering
Solid Biosciences $143.75 million follow-on equity offering
We advised the joint book-running managers on the stock offering
European Biotech Acquisition $120 million IPO
We advised European Biotech Acquisition, a SPAC, on its IPO and Nasdaq listing